At the conferences, Anumana will feature its FDA-cleared ECG-AI™ Low Ejection Fraction (LEF) algorithm and host expert panel discussions on the role of AI in clinical care. The company's ECG-AI platform includes a suite of algorithms designed to help clinicians detect cardiovascular diseases using ECG data. Anumana has also received FDA Breakthrough Device Designation for its pulmonary hypertension, cardiac amyloidosis, and hyperkalemia algorithms.
Key takeaways:
- Anumana, an AI-driven health technology company, will showcase its AI-powered cardiovascular solutions at the American Heart Association (AHA) Scientific Sessions 2024 and the North American Primary Care Research Group (NAPCRG) Annual Meeting.
- The company's ECG-AI algorithm uses a standard 12-lead ECG to detect low ejection fraction, a key indicator of heart failure, aiming to enable earlier diagnosis and treatment.
- At the conferences, Anumana will feature its FDA-cleared ECG-AI™ Low Ejection Fraction (LEF) algorithm and host expert panel discussions on the role of AI in clinical care.
- Anumana's ECG-AI platform includes a suite of algorithms designed to help clinicians detect cardiovascular diseases using ECG data, and has received FDA Breakthrough Device Designation for its pulmonary hypertension, cardiac amyloidosis, and hyperkalemia algorithms.